United in a Singular Mission

We are a diverse team of innovators in science, translational medicine and clinical development, dedicated to transforming the lives of patients faced with hard-to-treat cancers and autoimmune diseases.

Leadership

Our management team has decades of experience at leading biotechnology companies and a track record of success in navigating the complexities of drug development and delivering innovative medicines from bench to bedside.

 
Charlene_Liao.jpeg

Charlene Liao, PhD

Founder, CEO and Chair of the Board

Charlene has 25 years of industry experience in drug development and business leadership. From 2002-2016, Charlene held global drug development roles at Genentech where she was instrumental in leading development efforts across the product lifecycle for ten new molecular entities (NMEs) in a variety of therapeutic areas. Full Bio

LinkedIn

 

Barbara Klencke, MD

Chief Medical Advisor

Dr. Klencke is an Independent Board Member of Immune-Onc Therapeutics, Inc. and a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies. Since 2015, she has served as the chief medical officer of Sierra Oncology Inc., a publicly traded clinical-stage biopharmaceutical company recently acquired by GSK in 2022. From 2011 to 2015, Barbara served as senior vice president of global development at Onyx Pharmaceuticals, acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs while at Genentech, Inc. from 2003 to 2011. Full Bio

LinkedIn

 

Hong Xiang, PhD

Chief Development Officer

Hong joined Immune-Onc in Jan 2022 as SVP, Head of Development Sciences, and an Executive Committee (EC) member. She has demonstrated strategic leadership of our business and scientific leadership of our first-in-class pipeline. Hong has over 25 years of experience in all phases of drug development at both established and early-stage biotech companies. Prior to Immune-Onc, Hong was a functional area lead at Amgen and clinical pharmacology lead for bemarituzumab, a fast-track Phase 3 program in gastric and gastroesophageal junction cancer with multiple clinical studies in different combinations or in other tumor types.
Full Bio

LinkedIn

Founders

 

Board of Directors

 

Scientific Founder

 

Scientific Advisory Board